|
|
The DiaPrevent Research
Study Looking for options for someone between
10 and 20 years of age, recently diagnosed with Type 1 Diabetes? If you or a family member has been diagnosed with Type 1 Diabetes within the last three months, then
this clinical trial may be of interest to you. The
DiaPrevent research study aims to find out if the investigational study vaccine, named Diamyd, may preserve the body's ability
to produce insulin in children and young adults with Type 1 Diabetes. As in other research studies, the study vaccine
will be compared to a placebo (shots without the active drug). Two out of three participants will receive active study
vaccine and one out of three will receive placebo. There is a 66% chance you will receive the investigation study vaccine
Diamyd if you chose to participate in the study. This
study might be appropriate if you or a family member:
If you qualify for this study, you will receive one shot on 4 different occasions
and your diabetes will be monitored for a period of 2.5 years. All study-related procedures, laboratory tests, examinations
and the study drug will be provided at no cost. The DiaPrevent research study will include 320 participants at 30 to
50 sites across the United States. We hope that the DiaPrevent study will lead to advancements in the treatment of Type
1 Diabetes. For more information or to determine if
you qualify for this research opportunity, please call toll free 1-877-784-5302 or visit:  |
|
|